Where Will Cameco Stock Be in 5 Years?
Cameco (NYSE: CCJ) isn’t exactly the kind of stock you…
Buy
64
TGTX Quote, Financials, Valuation and Earnings
Last price:
$35.69
Seasonality move
:
-6.22%
Day range:
$34.83 - $36.06
52-week range:
$15.16 - $46.48
Dividend yield:
0%
P/E ratio:
146.42x
P/S ratio:
14.62x
P/B ratio:
23.51x
Volume:
1.3M
Avg. volume:
2.7M
1-year change:
108.55%
Market cap:
$5.6B
Revenue:
$329M
EPS (TTM):
$0.24
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
TGTX
TG Therapeutics
|
$117.9M | $0.17 | 101.13% | 653.48% | $41.20 |
|
ADMA
ADMA Biologics
|
$118.7M | $0.17 | 15.81% | 7.69% | $29.49 |
|
AXSM
Axsome Therapeutics
|
$119.3M | -$1.35 | 61.04% | -35.15% | $176.53 |
|
EDIT
Editas Medicine
|
$706.1K | -$0.59 | 251.82% | -54.6% | $3.38 |
|
OCGN
Ocugen
|
-- | -$0.06 | -69.33% | -41.68% | $6.50 |
|
OCUL
Ocular Therapeutix
|
$16.9M | -$0.28 | -20.3% | -33.34% | $17.42 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
TGTX
TG Therapeutics
|
$35.14 | $41.20 | $5.6B | 146.42x | $0.00 | 0% | 14.62x |
|
ADMA
ADMA Biologics
|
$19.77 | $29.49 | $4.7B | 23.26x | $0.00 | 0% | 10.54x |
|
AXSM
Axsome Therapeutics
|
$102.99 | $176.53 | $5.1B | -- | $0.00 | 0% | 11.51x |
|
EDIT
Editas Medicine
|
$1.87 | $3.38 | $156.5M | -- | $0.00 | 0% | 4.31x |
|
OCGN
Ocugen
|
$0.88 | $6.50 | $258M | -- | $0.00 | 0% | 54.63x |
|
OCUL
Ocular Therapeutix
|
$7.89 | $17.42 | $1.3B | -- | $0.00 | 0% | 22.17x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
TGTX
TG Therapeutics
|
-- | 1.159 | -- | 2.01x |
|
ADMA
ADMA Biologics
|
16.26% | 2.642 | 1.53% | 3.20x |
|
AXSM
Axsome Therapeutics
|
77.32% | 1.593 | 3.16% | 1.90x |
|
EDIT
Editas Medicine
|
-- | 0.641 | -- | 3.03x |
|
OCGN
Ocugen
|
63.49% | 0.941 | 13.41% | 2.24x |
|
OCUL
Ocular Therapeutix
|
20.65% | 0.643 | 5.93% | 9.89x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
TGTX
TG Therapeutics
|
$105.3M | $8.6M | 11.64% | 19.78% | 10.12% | -$28.7M |
|
ADMA
ADMA Biologics
|
$61.1M | $34.9M | 57.3% | 79.75% | 30.86% | -$24.4M |
|
AXSM
Axsome Therapeutics
|
$111.7M | -$55.5M | -103.06% | -309.19% | -46.91% | -$43.7M |
|
EDIT
Editas Medicine
|
-- | -$35.3M | -139.77% | -139.77% | -1585.92% | -$47.9M |
|
OCGN
Ocugen
|
-- | -$14.5M | -144.95% | -215.5% | -979.14% | -$19.4M |
|
OCUL
Ocular Therapeutix
|
$9.4M | -$63.9M | -46.82% | -56.05% | -570.85% | -$46.6M |
TG Therapeutics vs. Competitors
-
Which has Higher Returns TGTX or ADMA?
ADMA Biologics has a net margin of 4.19% compared to TG Therapeutics's net margin of 23.44%. TG Therapeutics's return on equity of 19.78% beat ADMA Biologics's return on equity of 79.75%.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics87.14% $0.03 $237.3M ADMAADMA Biologics53.22% $0.11 $445.9M -
What do Analysts Say About TGTX or ADMA?
TG Therapeutics has a consensus price target of $41.20, signalling upside risk potential of 17.25%. On the other hand ADMA Biologics has an analysts' consensus of $29.49 which suggests that it could grow by 49.17%. Given that ADMA Biologics has higher upside potential than TG Therapeutics, analysts believe ADMA Biologics is more attractive than TG Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics5 0 0 ADMAADMA Biologics2 1 0 -
Is TGTX or ADMA More Risky?
TG Therapeutics has a beta of 2.208, which suggesting that the stock is 120.838% more volatile than S&P 500. In comparison ADMA Biologics has a beta of 0.571, suggesting its less volatile than the S&P 500 by 42.882%.
-
Which is a Better Dividend Stock TGTX or ADMA?
TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. ADMA Biologics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or ADMA?
TG Therapeutics quarterly revenues are $120.9M, which are larger than ADMA Biologics quarterly revenues of $114.8M. TG Therapeutics's net income of $5.1M is lower than ADMA Biologics's net income of $26.9M. Notably, TG Therapeutics's price-to-earnings ratio is 146.42x while ADMA Biologics's PE ratio is 23.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 14.62x versus 10.54x for ADMA Biologics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics14.62x 146.42x $120.9M $5.1M ADMAADMA Biologics10.54x 23.26x $114.8M $26.9M
-
Which has Higher Returns TGTX or AXSM?
Axsome Therapeutics has a net margin of 4.19% compared to TG Therapeutics's net margin of -48.92%. TG Therapeutics's return on equity of 19.78% beat Axsome Therapeutics's return on equity of -309.19%.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics87.14% $0.03 $237.3M AXSMAxsome Therapeutics91.94% -$1.22 $234.6M -
What do Analysts Say About TGTX or AXSM?
TG Therapeutics has a consensus price target of $41.20, signalling upside risk potential of 17.25%. On the other hand Axsome Therapeutics has an analysts' consensus of $176.53 which suggests that it could grow by 71.4%. Given that Axsome Therapeutics has higher upside potential than TG Therapeutics, analysts believe Axsome Therapeutics is more attractive than TG Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics5 0 0 AXSMAxsome Therapeutics13 0 0 -
Is TGTX or AXSM More Risky?
TG Therapeutics has a beta of 2.208, which suggesting that the stock is 120.838% more volatile than S&P 500. In comparison Axsome Therapeutics has a beta of 0.456, suggesting its less volatile than the S&P 500 by 54.356%.
-
Which is a Better Dividend Stock TGTX or AXSM?
TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Axsome Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. Axsome Therapeutics pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or AXSM?
TG Therapeutics quarterly revenues are $120.9M, which are smaller than Axsome Therapeutics quarterly revenues of $121.5M. TG Therapeutics's net income of $5.1M is higher than Axsome Therapeutics's net income of -$59.4M. Notably, TG Therapeutics's price-to-earnings ratio is 146.42x while Axsome Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 14.62x versus 11.51x for Axsome Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics14.62x 146.42x $120.9M $5.1M AXSMAxsome Therapeutics11.51x -- $121.5M -$59.4M
-
Which has Higher Returns TGTX or EDIT?
Editas Medicine has a net margin of 4.19% compared to TG Therapeutics's net margin of -1633.49%. TG Therapeutics's return on equity of 19.78% beat Editas Medicine's return on equity of -139.77%.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics87.14% $0.03 $237.3M EDITEditas Medicine-- -$0.92 $62.4M -
What do Analysts Say About TGTX or EDIT?
TG Therapeutics has a consensus price target of $41.20, signalling upside risk potential of 17.25%. On the other hand Editas Medicine has an analysts' consensus of $3.38 which suggests that it could grow by 80.48%. Given that Editas Medicine has higher upside potential than TG Therapeutics, analysts believe Editas Medicine is more attractive than TG Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics5 0 0 EDITEditas Medicine4 8 0 -
Is TGTX or EDIT More Risky?
TG Therapeutics has a beta of 2.208, which suggesting that the stock is 120.838% more volatile than S&P 500. In comparison Editas Medicine has a beta of 2.149, suggesting its more volatile than the S&P 500 by 114.892%.
-
Which is a Better Dividend Stock TGTX or EDIT?
TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Editas Medicine offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. Editas Medicine pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or EDIT?
TG Therapeutics quarterly revenues are $120.9M, which are larger than Editas Medicine quarterly revenues of $4.7M. TG Therapeutics's net income of $5.1M is higher than Editas Medicine's net income of -$76.1M. Notably, TG Therapeutics's price-to-earnings ratio is 146.42x while Editas Medicine's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 14.62x versus 4.31x for Editas Medicine. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics14.62x 146.42x $120.9M $5.1M EDITEditas Medicine4.31x -- $4.7M -$76.1M
-
Which has Higher Returns TGTX or OCGN?
Ocugen has a net margin of 4.19% compared to TG Therapeutics's net margin of -1036.46%. TG Therapeutics's return on equity of 19.78% beat Ocugen's return on equity of -215.5%.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics87.14% $0.03 $237.3M OCGNOcugen-- -$0.05 $43.6M -
What do Analysts Say About TGTX or OCGN?
TG Therapeutics has a consensus price target of $41.20, signalling upside risk potential of 17.25%. On the other hand Ocugen has an analysts' consensus of $6.50 which suggests that it could grow by 635.79%. Given that Ocugen has higher upside potential than TG Therapeutics, analysts believe Ocugen is more attractive than TG Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics5 0 0 OCGNOcugen2 0 0 -
Is TGTX or OCGN More Risky?
TG Therapeutics has a beta of 2.208, which suggesting that the stock is 120.838% more volatile than S&P 500. In comparison Ocugen has a beta of 4.214, suggesting its more volatile than the S&P 500 by 321.428%.
-
Which is a Better Dividend Stock TGTX or OCGN?
TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocugen offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. Ocugen pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or OCGN?
TG Therapeutics quarterly revenues are $120.9M, which are larger than Ocugen quarterly revenues of $1.5M. TG Therapeutics's net income of $5.1M is higher than Ocugen's net income of -$15.4M. Notably, TG Therapeutics's price-to-earnings ratio is 146.42x while Ocugen's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 14.62x versus 54.63x for Ocugen. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics14.62x 146.42x $120.9M $5.1M OCGNOcugen54.63x -- $1.5M -$15.4M
-
Which has Higher Returns TGTX or OCUL?
Ocular Therapeutix has a net margin of 4.19% compared to TG Therapeutics's net margin of -598.74%. TG Therapeutics's return on equity of 19.78% beat Ocular Therapeutix's return on equity of -56.05%.
Company Gross Margin Earnings Per Share Invested Capital TGTXTG Therapeutics87.14% $0.03 $237.3M OCULOcular Therapeutix88.2% -$0.38 $335.1M -
What do Analysts Say About TGTX or OCUL?
TG Therapeutics has a consensus price target of $41.20, signalling upside risk potential of 17.25%. On the other hand Ocular Therapeutix has an analysts' consensus of $17.42 which suggests that it could grow by 120.74%. Given that Ocular Therapeutix has higher upside potential than TG Therapeutics, analysts believe Ocular Therapeutix is more attractive than TG Therapeutics.
Company Buy Ratings Hold Ratings Sell Ratings TGTXTG Therapeutics5 0 0 OCULOcular Therapeutix6 0 0 -
Is TGTX or OCUL More Risky?
TG Therapeutics has a beta of 2.208, which suggesting that the stock is 120.838% more volatile than S&P 500. In comparison Ocular Therapeutix has a beta of 1.508, suggesting its more volatile than the S&P 500 by 50.759%.
-
Which is a Better Dividend Stock TGTX or OCUL?
TG Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ocular Therapeutix offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. TG Therapeutics pays -- of its earnings as a dividend. Ocular Therapeutix pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios TGTX or OCUL?
TG Therapeutics quarterly revenues are $120.9M, which are larger than Ocular Therapeutix quarterly revenues of $10.7M. TG Therapeutics's net income of $5.1M is higher than Ocular Therapeutix's net income of -$64.1M. Notably, TG Therapeutics's price-to-earnings ratio is 146.42x while Ocular Therapeutix's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for TG Therapeutics is 14.62x versus 22.17x for Ocular Therapeutix. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income TGTXTG Therapeutics14.62x 146.42x $120.9M $5.1M OCULOcular Therapeutix22.17x -- $10.7M -$64.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Microsoft Stock Outlook, Azure & AI as Drivers of Long-Term Growth
Microsoft (NASDAQ:MSFT) has been among the top growth stocks of…
Is Tesla Stock Overvalued or a Buy for the Next Decade?
Shares of EV major Tesla (NASDAQ:TSLA) have experienced extreme volatility…
Stock Ideas
Buy
67
Is MSFT Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 39x
Buy
68
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 46x
Sell
39
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Alerts
Sell
10
EXOD alert for May 29
Exodus Movement [EXOD] is up 17.31% over the past day.
Buy
80
SBET alert for May 29
SharpLink Gaming [SBET] is up 181.07% over the past day.
Buy
90
BOX alert for May 30
Box [BOX] is up 1.38% over the past day.
